Moderna Shares Jump 212% After-Hours on Positive Cancer Vaccine Phase 3 Results
Moderna shares extended gains in after-hours trading after the company reported positive Phase 3 results for an mRNA-based cancer prevention treatment.
MRNA
Moderna ($MRNA) rallied sharply after announcing positive Phase 3 results for what was described as the first mRNA treatment to prevent cancer. The stock extended its advance to +212% on the day in after-hours trading.
The move added more than $50 billion to the company’s market capitalization on the day, according to the report.
The update highlights recent investor attention on mRNA-based oncology programs and their potential commercial impact.
Source: The Kobeissi Letter